Microbix’s Clot-Buster Drug Project Advances

Sequel Pharma Executes Agreement with CDMO for Drug Substance Production MISSISSAUGA, CANADA, March 14, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its funding and...

Microbix Enhances Quality Management System

ISO 13485:2016 Medical Devices Certification Attained TORONTO, December 24, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has attained the ISO 13485:2016 Medical Devices...

Microbix Reports Record Results for Q1 Fiscal 2024

Record Revenues of $8.4 million and Record Net Income of $2.5 million MISSISSAUGA, CANADA, February 14, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first...
Microbix’s Virtual AGM

Microbix’s Virtual AGM

Microbix will be hosting a virtual AGM on March 27, 2024, at 1:00 pm. The online link will allow shareholders to listen to the AGM and view a CEO presentation via Zoom. Shareholders without up-to-date computer access can listen-in via telephone by using the...

Microbix Achieves Further QAPs Sales Record

Over C$ 1 Million in One Shipment to a Leading Lab Accreditation Agency MISSISSAUGA, CANADA, January 3, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it has sold and shipped over...

Battling Flu Season: Quality Control and Microbix

Flu season is upon us, and with it comes the annual threat of influenza, respiratory syncytial virus (RSV), and more recently, the coronavirus, SAR-CoV-2. These viruses pose serious health risks to individuals around the world. The flu, in particular, can lead to a...

Microbix QAPs Supporting HPV Testing in Ireland

Distribution Partner Secures Contract Relating to Cervical Cancer Screening MISSISSAUGA, CANADA, October 27, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its quality...

Microbix Achieves New QAPs Sales Record

Over C$ 1 Million in Orders from Leading Diagnostics Industry Test-Maker MISSISSAUGA, CANADA, September 27, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has secured record...
Microbix Reports Results for Q3 Fiscal 2023

Microbix Reports Results for Q3 Fiscal 2023

Strong Sales of $5.5 million alongside Drug Partnering Agreement MISSISSAUGA, August 10, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and YTD...
Microbix Reports Results for Q2 Fiscal 2023

Microbix Reports Results for Q2 Fiscal 2023

Sales of $4.2 million and Profitability MISSISSAUGA, May 11, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2023 ended...

Trichomonas Vaginalis: Why Early Detection is Crucial

Trichomonas vaginalis, also known as trich, is a sexually transmitted infection (STI) caused by a parasitic protozoan. According to WHO more than 1 million new STIs are acquired every day and approximately 357 million people contract STIs each year. Despite its...

The Lowdown on STI Testing: What You Need to Know

Did you know that sexually transmitted infections (STIs) are shockingly common? Millions of cases are diagnosed every year, with young people and men who have sex with men being particularly at risk. And the scariest part? Many people don’t even know they have...

Microbix’s Multiplex Quality Control for STI Diagnosis

STIs: A public health issue  Sexually transmitted infections (STIs) are a significant public health issue, with millions of new cases diagnosed each year. Accurate and timely diagnosis is crucial to prevent the spread of these infections and ensure that patients...

Breaking the Stigma: Managing STIs for Better Sexual Health

Sexually transmitted infections (STIs) affect millions of people globally, yet there remains a significant amount of stigma around these infections. This stigma prevents people from discussing their STI status, leading to negative health outcomes and further spread of...

Revolutionizing Pandemic Preparedness with Self-Collection

Lessons from the COVID-19 Pandemic The COVID-19 pandemic has taught us that pandemics can be incredibly disruptive to our society, economy, and daily lives. In order to be better prepared for future pandemics, the whole industry has invested in scaling up the...

Diagnostics Explained: HPV

The Role of Diagnostics in HPV Screening The Importance of HPV Screening Human papillomavirus (HPV) is a common sexually transmitted infection that is linked to the development of cervical cancer. The primary screening for HPV infection is an important tool in the...

Diagnostics Explained: AMR

The Antimicrobial Resistance (AMR) crisis and how we can overcome it Antimicrobial Resistance (AMR) Antimicrobial resistance or AMR occurs when microorganisms build resistance to an antibiotic drug. With AMR on the rise, the World Health Organization has deemed this a...

Upcoming Events: Coming Soon

Here are all of Microbix’s upcoming events including conferences, trade shows, presentations, and more! Make sure to check regularly to stay up to date with the latest news from us!

Blog: Episode 3

In this episode of Diagnostics: Beyond the Lab we talk to Giorgio Triva, CEO and Strategic Project Manager of Copan Group, based in Italy, about what his company and the work it has done to become a global leader in sample collection, transport and test accuracy for...

Blog: Episode 2

In this episode of Diagnostic: Beyond the lab, we talk to Colin Denver, CEO of SpeeDX about antimicrobial resistance and using diagnostics to target treatment.

Blog: Episode 1

Diagnostics: Beyond the Lab In this episode we discuss the Human papillomavirus or HPV, vaccines, testing and cervical cancer. What is HPV and what is the way forward for testing?Joining us for this discussion is Larry Vaughan, director scientific affairs integrated...
About us

About us

ABOUT MICROBIX Microbix: Who we are? Microbix Biosystems Inc. develops and commercializes proprietary biological and technological solutions for human health and well-being. We manufacture a wide range of biological materials for the global diagnostics industry,...

Microbix Invests to Further Scale Its Business

Implementing MasterControl® and NetSuite® Solutions to Enable Rapid Growth MISSISSAUGA, CANADA, March 29, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces investment in programs to upgrade, digitize...

Virtual AGM on March 30, 2022

Once again, due to COVID -19 Pandemic, Microbix will be hosting a virtual AGM on March 30, 2022 at 1:00 pm.  The online link will allow shareholders to listen to the AGM and view a CEO presentation via Zoom.  Shareholders without up-to-date computer access can...

2022 AMMI Canada-CACMID Annual Conference – April 5-8

The time has come again for the Canadian annual meeting in infectious diseases and diagnostic microbiology. The AMMI Canada – CACMID Annual Conference is returning in a hybrid format: in-person in Vancouver, BC, and online via our virtual platform. The AMMI Canada –...

Microbix Launches Omicron Variant Test Control

Helping Ensure Workflow Accuracy of Tests for Respiratory Viruses MISSISSAUGA, CANADA, February 1, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces the expansion of its portfolio of Quality...

Microbix Posters at 31st ECCMID 2021

Two Posters Reporting on Cross-Platform Utility of Antigen & Serological QAPs™ Novel neutralizing anti-S1 SARS-CoV-2 human monoclonal antibody formulation for use as a cross-platform EQA sample and prospective Quality Controls Advanced SARS-CoV-2 nucleocapsid...

Microbix Presenting Product Results to Industry

Two Abstracts Reporting on Cross-Platform Utility of Antigen & Serological QAPs™ MISSISSAUGA, CANADA, July 8, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has been invited to present...

Microbix Announces $6.0 Million of Financings

$5.0 Million Bought-Deal Public Offering and $1.0 Million Private Placement – NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – MISSISSAUGA, April 28, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life...

Microbix & SpeeDx Form Exclusive Collaboration

Focus on Diagnostics and Controls for Anti-Microbial Resistant Infections MISSISSAUGA, CANADA and EVELEIGH, AUSTRALIA April 26, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, and SpeeDx Pty. Ltd. (SpeedDx),...

Virtual AGM on March 30, 2021

Once again, due to COVID -19 Pandemic, Microbix will be hosting a virtual AGM on March 30, 2021 at 1:00 pm.  The online link will allow shareholders to listen to the AGM and view a CEO presentation via Zoom.  Shareholders without up-to-date computer access can...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Why We Need To Test COVID-19 Tests

During the first peak of the coronavirus pandemic, it became apparent that the processing of the standard COVID-19 test using nasal swab samples, while considered a gold standard, was slow, taking over 24 hours to give results in most cases. As demand for quicker test...

Microbix Reports Results for Q1 Fiscal 2021

Record Q1 Sales, With Nearly 3,600% Year-Over-Year QAPs Growth MISSISSAUGA, February 11, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, reports results for the first quarter of its fiscal 2021, the...

Microbix Viral Transport Medium Now Available

Initial Capacity of 50,000 Vials/Week under Health Canada Regulation MISSISSAUGA, January 28, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce the commercial availability of its viral...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Reports Results for Fiscal 2020

Full-Year Sales of $10.5 Million, QAPs Sales Grow by 41%   MISSISSAUGA, December 18, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating...

Microbix Discloses New Products, Sales, And Capacity

Sales Of QAPs™ Kits To Help Qualify Multi-Pathogen Respiratory Test Systems MISSISSAUGA, CANADA, October 29, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the availability and initial material...

Microbix Announces Extension Of Warrant Expiry Dates

Applies For 12-Month Term Extension Of October 2015 And October 2017 Warrants MISSISSAUGA, CANADA, September 17, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an award-winning life sciences innovator and exporter, announces it has applied...

Microbix Announces Board Changes

William J. Gastle Retiring, Martin Marino Nominated To Become Independent Chairman MISSISSAUGA, CANADA, September 15, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an award-winning life sciences innovator and exporter, announces that its founder...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Q3 Fiscal 2020

Year-Over-Year QAPs Sales Growth of 141% for Q3 MISSISSAUGA, August 14, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, reports results for its third quarter and year to date fiscal 2020 (Q3 and YTD)...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Curious To See How We Perform A COVID Test?

Curious to see how we perform a COVID test? The video shows the laboratory steps involved in testing four patient samples along with one Control. The reagents and procedures are for the “CDC test” for SARS-CoV-2. Still, there is no difference in processing these...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Shares Become Available For U.S. Investors

OTC Markets Listing and DTC Electronic Clearance Eligibility MISSISSAUGA, ON, CANADA, July 14, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an award-winning life sciences innovator and exporter, announces that it has completed two processes to...

2020 AGM Meeting Notice

Please note, due to the global circumstances, this year’s Microbix Annual General Meeting will be held as a virtual meeting. Please stay tuned for link and instructions.

Microbix Engaged To Develop & Supply Custom QAPs™

Instrument-Specific Controls to Support Rapid Tests for Viral Respiratory Pathogens MISSISSAUGA, June 1, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it has been engaged to develop and...

Microbix Expanding QAPs™ Production Capacity

Build-out to Support Tenfold Increase Now Underway MISSISSAUGA, CANADA, May 27, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it has begun a build-out of its second facility that is...

Microbix Reports Results For Q2 Fiscal 2020

Timing of Product Shipments Affects Results MISSISSAUGA, May 14, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, reports results for its second quarter and first half of fiscal 2020 (“Q2” and “H1”)...

Microbix COVID-19 QAPs Now Available for U.S. Labs

Registration Enables Immediate Usage of SARS-CoV-2 Controls by U.S. Clinical Labs MISSISSAUGA, CANADA, May 7, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, is pleased to announce U.S. availability of its...

Microbix Participating In COVID-19 Virtual Conference

Presentation and Panel Participation at Adelaide Capital Event on April 23 MISSISSAUGA, CANADA, April 21, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it will be participating in the...

Microbix Annual General Meeting Process Update

Remote Access to the AGM Provided to Avoid Physical Attendance MISSISSAUGA, March 25, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Reports Results For Q1 Fiscal 2020

Positive Cash Flow from Operations Achieved MISSISSAUGA, February 13, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices...

Annual General Meeting (AGM) – March 31st, 2020 UPDATE!

The AGM will still be held on March 31, 2020 at 1:00 pm, however due to the closure of our planned venue and alternative venues, we will be proceeding with access being provided online or via teleconference only. Due to the COVID-19 pandemic, Microbix also wants to...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Reports Results For Fiscal 2019

Full-Year Sales of $13.4 Million, Progress Toward Sustained Profitability MISSISSAUGA, December 20, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics...

Microbix Wins Ontario Business Award

2019 “OBAA” for Excellence in Export Strategy MISSISSAUGA, November 18, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices...

Microbix Presenting At StableView TECH19 Conference

Meetings with Growth-Oriented Investors, October 3, 2019 MISSISSAUGA, October 1, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of clinical diagnostic materials and quality control medical devices, announces that it will be presenting to...

Microbix Presenting At Muskoka Capital Conference – 2019

Meetings with Growth-Oriented Investors, September 27-29, 2019 MISSISSAUGA, September 25, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of clinical diagnostic materials and medical devices for test quality control, announces that it will be...

Microbix Quality Products Enter U.S. Market

Four IVD Controls to Support Performance of Human Papilloma Virus (HPV) Tests MISSISSAUGA, September 19, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, is pleased to announce U.S. availability of four...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Reports Results For Q3 Fiscal 2019

Q3 Sales of $3.1 Million and $9.8 Million Year-To-Date TORONTO, August 12, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its third quarter and nine months of fiscal 2019, the...

Microbix Provides Bioreactor Update

Largest Customer Confirms Conversion Timetable & Provides Full-Scale Order TORONTO, August 1, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, provides an update on the conversion of its...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Reports Results For Q2 Fiscal 2019

Record Sales of $4.25 Million, Sales Growth of 42%, and Material Net Earnings TORONTO, May 13, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its second quarter and first half of...

Microbix Announces Management Changes

Ken Hughes Appointed COO, Kathryn Froh Retiring TORONTO, April 18, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has appointed Dr. Kenneth (Ken) Hughes as its Chief Operating...

Microbix Will Be Exhibiting At The 29th Annual ECCMID

Microbix will be exhibiting at the 29th annual ECCMID (European Congress of Clinical Microbiology and Infectious Disease) in Amsterdam on April 13-16th. We are showcasing our recently launched line of QAPs™ (Quality Assessment Products) used in a range of infectious...

Annual General Meeting (AGM) – March 27th, 2019

Shareholders and other interested parties, please note Microbix will hold its annual general meeting (AGM) at the Toronto University Club located at 380 University Avenue, Toronto, M5G 1R6 on Wednesday March 27th at 1 PM. Click here for INFO CIRCULAR
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Reports Results For Q1 Fiscal 2019

Lower Sales, Improving Gross Margin, Positive Cash Flow from Operations TORONTO, February 12, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its first quarter of fiscal 2019, the...

Microbix Enhances Quality Management System

ISO 13485:2016 Medical Devices Certification Attained TORONTO, December 24, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has attained the ISO 13485:2016 Medical Devices...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Reports Results For Fiscal 2018

Full-Year Sales Growth of 23%, Progress Toward Sustained Profitability TORONTO, December 21, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its fourth quarter of fiscal 2018, the...

Microbix Wins Business Award Of Excellence

Recognized with 2018 Business Innovation Award by MBOT TORONTO, November 19, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has been recognized with the 2018 Business Innovation...

Microbix Exhibiting At MEDICA Trade Fair

Showcasing Antigen and Quality Assessment Products TORONTO, November 6, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it will be exhibiting its antigens and quality assessment products...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Reports Record Third Quarter Sales

Microbix Reports Record Third Quarter Sales Year-Over-Year Sales Growth of 24% in First Nine Months   TORONTO, August 14, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports financial results for...

Microbix Exhibiting At AACC Exposition

Showcasing New Quality Assessment Products TORONTO, July 26, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it will be exhibiting its Quality Assessment Products (QAPs™) at the 70th...

Microbix To Present At Okanagan Capital Conference

Conference Introduces Growth Companies to Investors, July 12-14, 2018 TORONTO, July 12, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it will be presenting to investors about Microbix...

Microbix Completes Multiple Facility Upgrades

Production Capacity Increased to Support Growth Objectives TORONTO, May 8, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces the completion of multiple upgrades to its production facility, to...

Microbix To Present At Bloom Burton Conference

Healthcare Investor Conference in Toronto on April 30 & May 1 TORONTO, April 29, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that its CEO, Cameron Groome, has been invited to present...

Microbix Engages Drug Licensing Advisor

Torreya Partners to Assist with Kinlytic® urokinase TORONTO, April 26, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces the engagement of Torreya Partners LLC of New York to assist it in...

ECCMID Madrid, Spain April 21-24

Join us at ECCMID in Madrid in April. It will be our first time exhibiting there and our QAPs™ lines will be our highlighted. For more information, visit http://www.eccmid.org/

Microbix Featured At Cantech Investment Conference

Invited onto Panel about Managing Canadian Healthcare Companies for Growth TORONTO, January 29, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces its participation as a panelist and exhibitor...

Cantech Investor Conference

JANUARY 29, 2018 Celebrating the 5th anniversary of Canada’s largest technology investment conference. We are excited to bring over 3500 engaged investors together with 100+ leading technology companies. Visit us at the Metro Toronto Convention Center on January 31...

Microbix Expands Quality Assessment Product Family

  48 New Products Being Added, Under PTDx™ and PROCEEDx™ Brands TORONTO, January 18, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces the expansion of its quality assessment product...

Microbix To Amend Share Purchase Warrant Terms

TORONTO August 24 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, announces it has applied to the TSX to amend the terms of 1,500,000 common share purchase warrants (the “Warrants”) issued in connection...